ArticleJournal of bone and mineral metabolism2020
Management manual for cancer treatment-induced bone loss (CTIBL): position statement of the JSBMR.
Article in Journal of bone and mineral metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer.ESMO open · 2022Guideline
- Romosozumab for cancer treatment-induced bone loss in postmenopausal women with hormone receptor-positive breast cancer: a case series.Archives of osteoporosis · 2026Article
- Management of bone health in cancer survivorship: a systematic review of clinical guidelines.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Review
- Article
- Bone Health Management in Men Commencing Androgen Deprivation Therapy for Prostate Cancer and Women Commencing Anti-Oestrogen Therapy for Breast Cancer.Cancer medicine · 2025Review
- Longitudinal assessment of bone mineral density in prostate cancer patients: comparing metastatic and non-metastatic regions.International journal of clinical oncology · 2025Observational
- Effect of bisphosphonate and denosumab treatment on TBS in Japanese breast cancer patients with AIBL.Journal of bone and mineral metabolism · 2024Article
- Temporal declines in bone mineral density and trabecular bone score during androgen deprivation therapy.Journal of bone and mineral metabolism · 2024Article
- Efficacy of a single 5 mg zoledronic acid infusion in preventing bone loss and fracture in postmenopausal women with breast cancer.Journal of bone and mineral metabolism · 2024Observational
- Cancer treatment-induced bone loss.The Korean journal of internal medicine · 2024Review
- Chemotherapy effects on bone mineral density and microstructure in women with breast cancer.Journal of bone and mineral metabolism · 2024Observational
- Androgen deprivation therapy-related fracture risk in prostate cancer: an insurance claims database study in Japan.Journal of bone and mineral metabolism · 2024Article
- Validation of JSBMR's CTIBL manual for Japanese men receiving androgen deprivation therapy for prostate cancer.Journal of bone and mineral metabolism · 2023Article
- Cancer Treatment-induced Bone Loss in the Elderly: Progress and Ongoing Challenges.Internal medicine (Tokyo, Japan) · 2023Article
- Fanconi Syndrome Associated with Long-term Treatment with Zoledronate.Internal medicine (Tokyo, Japan) · 2023Article
- Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer.Journal of bone and mineral metabolism · 2023Review
- Assessment of bone health in patients with prostate cancer using cancer staging computed tomography.Journal of bone and mineral metabolism · 2022Article
- Article
- Effects of Soft Tissue Sarcoma and Doxorubicin on Bone Metabolism in Mice.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Androgen deprivation therapy and aromatase inhibitors are known to cause a decrease in bone mineral density and an increase in fractures. Patients receiving these treatments have been shown to have a fracture risk equal to or greater than that of patients with osteoporosis with prevalent fractures. This manual was created to prevent fractures in patients with cancer treatment-induced bone loss with high fracture risks who cannot be treated under the current Japanese guideline for the prevention and treatment of osteoporosis. This manual recommends drug treatment for patients with BMD - 2.0 ≤ T score < - 1.5 with the family history of hip fracture or 15% or more 10-year probability of major osteoporotic fractures by FRAX
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.